VERU INC.VERUEarnings & Financial Report
Veru Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for oncology, urology, and men’s and women’s health conditions. Its core product pipeline includes targeted therapies for breast and prostate cancer, as well as treatments for reproductive health disorders, serving patients primarily across North America and European markets.
Revenue
$0
Gross Profit
N/A
Operating Profit
$-8.1M
Net Profit
$-7.9M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.05
VERU INC. Q2 FY2025 Financial Summary
VERU INC. reported revenue of $0 for Q2 FY2025, with a net profit of $-7.9M (up 21.2% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-7.9M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 FY2025 |
VERU INC. Annual Revenue by Year
VERU INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $16.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $16.9M |
| 2023 | $16.3M |
| 2022 | $39.4M |
VERU INC. Quarterly Revenue & Net Profit History
VERU INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-7.3M | N/A |
| Q2 FY2025 | $0 | — | $-7.9M | N/A |
| Q4 FY2024 | $6.7M | +72.4% | $-8.5M | -128.2% |
| Q3 FY2024 | $4.0M | +18.3% | $-11.0M | -277.4% |
| Q2 FY2024 | $4.1M | -37.2% | $-10.0M | -242.4% |
| Q1 FY2024 | $2.1M | -14.6% | $-8.3M | -386.6% |
| Q4 FY2023 | $3.9M | +49.2% | $-8.1M | -210.6% |
| Q3 FY2023 | $3.3M | -65.2% | $-12.5M | -374.8% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M | $3.9M | $2.1M | $4.1M | $4.0M | $6.7M | $0 | $0 |
| YoY Growth | -65.2% | 49.2% | -14.6% | -37.2% | 18.3% | 72.4% | N/A | N/A |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $60.2M | $50.0M | $80.6M | $71.8M | $64.6M | $60.4M | $32.7M | $27.3M |
| Liabilities | $39.6M | $30.3M | $29.0M | $26.6M | $27.0M | $28.1M | $11.6M | $12.0M |
| Equity | $20.6M | $19.7M | $51.6M | $45.2M | $37.6M | $32.3M | $21.0M | $15.3M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-18.4M | $-9.5M | $-6.0M | $-5.7M | $-5.6M | $-4.4M | $-7.7M | $-5.5M |